Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib for Prurigo Nodularis and CPUO
NCT05038982Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abrocitinib in prurigo nodularis (PN), chronic pruritus of unknown origin (CPUO), sponsored by Johns Hopkins University. Started Sep 2021; status: completed.
02
Drugs
abrocitinib
03
Conditions
prurigo nodularis (PN)chronic pruritus of unknown origin (CPUO)
Beyond the preview
Go deeper on NCT05038982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038982.